 HOUSTON--BUSINESS WIRE--Kiromic Biopharma, Inc. Nasdaq: KRBP, a target discovery and gene-editing company utilizing artificial intelligence and proprietary neural network platform with a therapeutic focus on immuno-oncology, announces the filing of key European patents for its chimeric PD-1 chPD1 target. Kiromic chPD1 receptor targets PD-1 ligands expressed on many different types of cancer cells, including ovarian, pancreatic, prostate, colon, kidney, and breast cancer and melanoma. Kiro 